-
321
-
322
-
323
-
324
Nanomechanical characterization of soft nanomaterial using atomic force microscopy
Published 2025-04-01Get full text
Article -
325
Assessing the Economic Burden and Health Care Utilizations of U.S. Veteran Patients with Schizophrenia
Published 2013-10-01“…Patients in both groups were required to be at least age 18 years and have continuous medical and pharmacy benefits 1 year pre- and 1 year post-index date. …”
Get full text
Article -
326
-
327
-
328
-
329
-
330
Impact of Oxycodone HCl Extended-release Formulary Restrictions on Extended-release Opioid Market Share, Healthcare Resource Utilization and Costs in Commercial and Medicare Plans
Published 2017-07-01“…**Background:** Previous research demonstrated that utilization management (UM) such as prior authorization (PA) or non-formulary (NF) restrictions may reduce pharmacy costs when designed and applied appropriately to certain drug classes. …”
Get full text
Article -
331
Lung-homing nanoliposomes for early intervention in NETosis and inflammation during acute lung injury
Published 2025-02-01Get full text
Article -
332
-
333
Economic Burden of HIV in a Commercially Insured Population in the United States
Published 2023-01-01“…All-cause costs PPPM for adults with PrEP were $1761 ($1938), with pharmacy costs accounting for 71%. **Conclusions:** Despite advances in ART, patients with newly diagnosed HIV and at-risk patients receiving PrEP continue to incur HRU costs. …”
Get full text
Article -
334
Leveraging AlphaFold for innovation and sustainable health research in Africa
Published 2025-02-01Get full text
Article -
335
War-related eye trauma: a study of civilian and military cases from Ukraine's ongoing conflict
Published 2025-02-01Get full text
Article -
336
-
337
-
338
Evaluation of Treatment Patterns and Maintenance Dose Titration Among Patients With Crohn’s Disease Initiating Biologics With 3 Years of Follow-Up
Published 2023-11-01“…**Methods:** This retrospective observational study was conducted using the STATinMED RWD Insights all-payer medical and pharmacy data. Adult patients with at least 1 CD medical claim and at least 1 medical/pharmacy claim for a biologic (adalimumab \[ADA\], certolizumab pegol (CZP), infliximab \[IFX\] and its biosimilar products \[IFX-BS\], ustekinumab \[UST\], and vedolizumab \[VDZ\]) between September 2016 and October 2018 were identified. …”
Get full text
Article -
339
-
340